What Is Fanconi Anemia? Symptoms, Causes & Treatment

Fanconi anemia is a rare inherited disorder in which the body’s ability to repair a specific type of DNA damage is broken, leading to bone marrow failure, a high risk of cancer, and a range of birth defects that can affect the skeleton, organs, and growth. First described by Swiss pediatrician Guido Fanconi in 1927, the condition has since been traced to mutations in more than 20 different genes, all of which feed into a single DNA-repair system. Despite its rarity, the genetics and biology of Fanconi anemia have had an outsized influence on our understanding of how DNA repair works in everyone, and the disease is now at the frontier of gene therapy research.

How It Happens at the Genetic Level

Fanconi anemia is caused by defects in the repair of DNA interstrand crosslinks, which are bonds that glue the two strands of the DNA double helix together in places they should not be joined. These crosslinks block the cell’s machinery from reading or copying DNA, and when left unrepaired they cause severe genome instability.¹ The body has an elaborate chain of proteins dedicated to detecting and fixing these crosslinks. In a person with Fanconi anemia, one link in that chain is missing or nonfunctional.

Biallelic mutations (meaning both copies of a gene are affected) in 21 different genes have been linked to the disease, along with one gene on the X chromosome.² The vast majority of cases follow an autosomal recessive inheritance pattern: a child must receive a defective copy of the same gene from each parent to develop the disease. Carriers, who have only one defective copy, are typically healthy. In the United States, roughly 1 in 181 people carry a mutation in one of the Fanconi anemia genes, which is considerably higher than the older estimate of about 1 in 300.³ Carrier rates are even higher in certain founder populations, including Ashkenazi Jews, where rates approach roughly 1 in 100.

Despite these carrier frequencies, the disease itself is quite rare. An estimated 550 to 975 people were living with Fanconi anemia in the United States as of 2010, reflecting how uncommon it is for two carriers to have a child together and for that child to inherit both defective copies.³

Physical Signs That Appear at Birth

Many children with Fanconi anemia are born with visible structural differences, though the specific combination varies widely from person to person. Some individuals have no obvious physical signs at all, which is one reason the diagnosis can be delayed.

The most characteristic birth defect involves the thumb and forearm. Roughly half of all patients are born with anomalies of the thumb, the radius bone, or both.⁴ In a detailed study of 48 patients, more than half had hand differences, and every one of those patients had an abnormal thumb. Bilateral abnormalities were much more common than one-sided ones, and the severity ranged from a slightly small thumb to a completely absent thumb with underdevelopment of the radius.⁵ Some children had duplicate thumbs on one hand and a hypoplastic thumb on the other. In the most severe cases, multiple fingers and most of the radius were missing.

Beyond the hands, other congenital features can include short stature, café-au-lait skin spots (flat pigmented patches), kidney malformations, heart defects, and abnormalities of the ear that may affect hearing. The condition was originally described in 1927 alongside short stature and skin hyperpigmentation, and those remain common findings.⁶ But no single birth defect is present in every patient, and roughly a quarter of people with genetically confirmed Fanconi anemia have no obvious physical anomalies at all. That variability makes the structural signs a useful clue rather than a reliable diagnostic checklist.

Bone Marrow Failure

The most medically urgent feature of Fanconi anemia is progressive bone marrow failure. The bone marrow is where blood cells are produced, and in children with this condition, the stem cells responsible for making blood gradually decline in number and function. This process typically becomes apparent during childhood, and it worsens over time. Researchers have found that the pool of blood-forming stem cells in people with Fanconi anemia starts out smaller than normal, shrinks further with age, and eventually approaches near-zero levels in a pattern not seen in healthy individuals.⁷

The mechanism involves an overactive DNA damage alarm system. The p53 protein, which normally monitors cells for DNA errors and tells damaged cells to stop dividing, is hyperactivated in Fanconi anemia stem cells. Because these cells cannot properly repair the crosslinks that naturally occur in DNA during normal metabolism, the p53 alarm fires constantly and forces more and more stem cells into permanent retirement or death. The result is a steadily shrinking factory for blood production.

Clinically, this shows up first as low blood counts: anemia (too few red blood cells), thrombocytopenia (too few platelets, leading to easy bruising and bleeding), and neutropenia (too few white blood cells, increasing infection risk). By age 40, the cumulative risk of developing marrow failure exceeds 50% for patients with the most common genetic subtypes.⁸

Cancer Risk

Fanconi anemia carries a strikingly elevated risk of certain cancers. The same DNA repair deficiency that causes marrow failure also leaves cells vulnerable to accumulating the kinds of mutations that drive cancer. Two categories of cancer are the main concern: blood cancers and solid tumors.

Among blood cancers, acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS, a precancerous bone marrow condition) are the primary threats. By age 40, the cumulative risk of AML in the most common Fanconi anemia subtypes is about 20%.⁸ Certain chromosomal changes detected through routine monitoring can serve as early warning signs of progression toward leukemia, which is why regular bone marrow surveillance is recommended.⁹

Among solid tumors, head and neck squamous cell carcinoma stands out as the single most common cancer type. The incidence is estimated at 500-fold to 700-fold higher than in the general population.¹⁰¹¹ Gynecologic squamous cell cancers also occur at elevated rates. By age 40, the cumulative risk of developing a solid tumor reaches about 30%.⁸ These cancers tend to appear at much younger ages than they would in the general population, often striking in the teens or twenties.

Treating cancer in Fanconi anemia patients is complicated by their underlying DNA repair defect. Standard chemotherapy and radiation work in part by creating DNA damage that kills cancer cells, but Fanconi anemia patients are hypersensitive to these treatments. Doses that would be routine for someone without the condition can cause life-threatening toxicity. Oral surveillance appears to help catch tumors at earlier stages: patients in one review who were under active oral screening were typically diagnosed with stage I or II disease, while those not under surveillance often presented with stage III or IV tumors.¹²

How the Diagnosis Is Made

The standard diagnostic test for Fanconi anemia exposes a blood sample to chemicals called diepoxybutane (DEB) or mitomycin C (MMC), both of which create the DNA crosslinks that Fanconi anemia cells cannot repair.¹³ In a healthy person’s cells, the repair machinery handles these crosslinks without much trouble. In cells from a person with Fanconi anemia, the damage accumulates and the chromosomes visibly break apart at a much higher rate. Counting these breaks under a microscope gives a clear yes-or-no answer. The test is also useful for screening children with unexplained bone marrow failure, even when the classic physical signs are absent.¹⁴

After a positive chromosome breakage test, genetic sequencing identifies which specific gene is mutated. This matters for treatment planning: some subtypes (particularly FANCD1/BRCA2) carry different cancer risks and may require different surveillance schedules than the more common FANCA subtype, which accounts for roughly two-thirds of all cases.

Treatment for Bone Marrow Failure

A stem cell transplant from a matched donor remains the only cure for the bone marrow failure component of Fanconi anemia. However, the conditioning regimens used to prepare a patient’s body for transplant have historically been a problem. Standard high-dose chemotherapy and total body irradiation are dangerously toxic for these patients. Over the past two decades, reduced-intensity protocols using the drug fludarabine combined with lower doses of cyclophosphamide have transformed outcomes. One such protocol reported prompt engraftment with minimal toxicity in patients receiving transplants from both sibling and unrelated donors.¹⁵

Timing matters enormously. A single-center study using fludarabine-based conditioning found that transplants performed for aplastic anemia (marrow failure before it progresses to cancer) achieved a five-year overall survival above 85%, while transplants performed after MDS or AML had already developed showed five-year survival closer to 46%.¹⁶ This stark difference is a major reason clinicians push for regular blood count monitoring and early discussion of transplant timing with families.

For patients who are not yet candidates for transplant, or who lack a suitable donor, androgens can temporarily boost blood counts. Oxandrolone, a synthetic androgen, produced a hematologic response in about three-quarters of patients in a small study, with side effects that were generally mild and manageable with dose adjustments.¹⁷ Oxymetholone, another androgen, has also been used for decades and can improve blood counts, but research in animal models suggests it works partly by stimulating dormant stem cells to divide, which over time may exhaust the remaining stem cell reserve.¹⁸ Androgens are therefore typically viewed as a bridge to transplant, not a permanent solution.

Gene Therapy

The most exciting recent development in Fanconi anemia treatment is gene therapy. The idea is to take a patient’s own blood stem cells, insert a working copy of the defective gene using a lentiviral vector, and return the corrected cells to the patient. Because the corrected cells can repair crosslinks and the uncorrected ones cannot, the corrected cells have a natural growth advantage and gradually take over blood production, potentially without the need for the harsh conditioning regimens required in a traditional transplant.¹⁹

A clinical trial in patients with the FANCA subtype demonstrated that this approach works in humans. Gene-corrected stem cells engrafted and expanded in patients who received no conditioning at all. The corrected cells showed acquired resistance to DNA crosslinking agents, confirming functional repair. In patients with the highest levels of corrected cells, progression of bone marrow failure was halted.²⁰

Updated results from ongoing global trials of the gene therapy product fanca-cel (mozafancogene autotemcel) have shown progressive and sustained genetic correction in the majority of treated patients with sufficient follow-up, along with evidence of hematologic stabilization.²¹ Some patients showed phenotypic correction developing slowly over years, consistent with the corrected cells gradually outcompeting the uncorrected ones. Gene therapy is not yet widely available for Fanconi anemia, but the trajectory is encouraging. It is worth noting that gene therapy currently addresses only the bone marrow failure; it would not be expected to reverse congenital structural anomalies or eliminate the cancer risk in tissues outside the blood system.

Endocrine and Metabolic Problems

Fanconi anemia affects far more than the blood. About 80% of children and adults with the condition have at least one endocrine abnormality.²² Short stature is the most visible manifestation, present in roughly half of patients, sometimes linked to growth hormone deficiency. Thyroid underactivity affects more than a third. Abnormal glucose and insulin metabolism occurs in a similar proportion and can evolve toward diabetes.

A comprehensive study found that dyslipidemia (abnormal cholesterol and fat levels) was present in over half of patients, obesity in about a quarter, and metabolic syndrome in about a fifth. Among patients who had reached or passed puberty, roughly two-thirds had some form of gonadal dysfunction. Perhaps most striking, more than 90% of adult patients had osteopenia or osteoporosis, conditions typically associated with much older age.²³ These findings have led to recommendations that an endocrinologist be part of every Fanconi anemia patient’s care team, with routine screening for growth, thyroid function, glucose metabolism, bone density, and puberty.²²

The Aldehyde Connection

One of the more fascinating discoveries about Fanconi anemia involves a surprising everyday metabolite: acetaldehyde, the compound your body produces when it breaks down alcohol, and which cells also generate as a normal byproduct of metabolism. Research in mice showed that animals lacking both the Fanconi anemia repair pathway and the main enzyme that detoxifies acetaldehyde (ALDH2) developed devastating bone marrow failure and a more than 600-fold reduction in their blood stem cell pool.²⁴

This finding suggested that the bone marrow failure in Fanconi anemia is not simply the result of random DNA crosslinks from unknown sources. It may be driven in large part by endogenous aldehydes, reactive molecules that the body produces constantly during normal metabolism and which, without proper detoxification and repair, damage the DNA of blood stem cells. A newly described human condition called Aldehyde Degradation Deficiency Syndrome, found in Japanese children with combined defects in aldehyde-degrading enzymes, overlaps clinically with Fanconi anemia and reinforces this idea.²⁵ The practical implication is that alcohol, which floods the body with acetaldehyde, could be particularly harmful for people with Fanconi anemia, and genetic variants in ALDH2 (common in East Asian populations) may modify disease severity.

Fertility and Pregnancy

Gonadal dysfunction is common in Fanconi anemia, and fertility is reduced for both men and women. In a review of over 110 women with Fanconi anemia who had reached at least 16 years of age, about 15% became pregnant. Those pregnancies produced 19 births and 18 surviving children. Anemia and low platelet counts worsened during pregnancy in some patients but improved afterward in about half of those cases, and there were no deaths during delivery itself.²⁶

For patients who have undergone a stem cell transplant, the conditioning regimen can further damage the ovaries or testes, but recovery is possible. Clinicians recommend regular hormonal monitoring after transplant and counseling about fertility preservation options, including ovarian tissue cryopreservation before transplant and assisted reproduction techniques.²⁷ Pregnancy in a person with Fanconi anemia carries real risks, particularly related to blood counts, but is not categorically impossible.

Living with a Rare Disease

The psychological burden of Fanconi anemia is substantial and often underrecognized. In interviews with adults living with the condition, five recurring themes emerged: the feeling that Fanconi anemia is all-encompassing, the toll of stigma and trauma on mental health, the bittersweet quality of connecting with others who share the diagnosis, barriers to accessing mental healthcare, and the slow process of accepting the disease. A particularly consistent complaint was the difficulty finding mental health professionals who understand rare diseases. Participants described feeling that their experiences were outside the frame of reference of most therapists.²⁸

The transition from pediatric to adult care is another challenge. Many patients are diagnosed in childhood and managed at specialized pediatric centers, but once they reach adulthood, they may find themselves seeing clinicians who have never encountered the disease. Given the need for lifelong cancer screening, endocrine monitoring, and (in transplanted patients) management of graft-related complications, finding a coordinated adult care team can be a struggle. Patient organizations play an important role in connecting families, funding research, and maintaining disease registries that have been critical for understanding the natural history and treatment outcomes of a condition this rare.